CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 30, 2010
Result type: Reports
Project Number: SR0218-000
Product Line: Reimbursement Review

Generic Name: Roflumilast

Brand Name: Daxas

Manufacturer: Nycomed Canada Inc.

Therapeutic Area: Chronic obstructive pulmonary disease

Indications: Chronic obstructive pulmonary disease (COPD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 27, 2011

Recommendation Type: Do not list